Patrys CEO and MD, Dr James Campbell, was interviewed by Proactive’s Andrew Scott today to discuss the importance of the Company’s news that it has now developed and optimised a stable cell line for production of our full-sized IgG deoxymab, PAT-DX3.
Check out the interview here: